中国医药导报
中國醫藥導報
중국의약도보
China Medical Herald
2015年
31期
17-20,24
,共5页
吕东升%张峰%马睿婷%赵美荣%黄小军%王志纲%云晓彬
呂東升%張峰%馬睿婷%趙美榮%黃小軍%王誌綱%雲曉彬
려동승%장봉%마예정%조미영%황소군%왕지강%운효빈
齐拉西酮%血药浓度%高效液相色谱法%临床疗效
齊拉西酮%血藥濃度%高效液相色譜法%臨床療效
제랍서동%혈약농도%고효액상색보법%림상료효
Ziprasidone%Plasma concentration%High performance liguid chromatography%Clinical efficacy
目的:探讨齐拉西酮的血药浓度测定方法及其临床应用。方法选取2011年10月~2013年7月期间内蒙古精神卫生中心住院的30例蒙古族分裂症患者为研究对象。采用高效液相色谱法分别于齐拉西酮治疗第1、2、4周末测定患者体内齐拉西酮浓度,同时采用阳性与阴性症状量表(PANSS)和治疗时出现的不良反应量表(TESS)来评估临床疗效和不良反应。结果齐拉西酮血药浓度在40~640 ng/mL范围内与峰面积呈现良好的线性关系(r=0.99),最低定量浓度为18 ng/mL,日内日间误差均小于10%。第4周周末所测齐拉西酮浓度与相应的PANSS减分率、日平均剂量呈显著正相关(r>0.4,P<0.05)。结论所使用的高效液相色谱法具有简单、稳定和准确的特点,而且患者体内齐拉西酮浓度具有良好的量效关系,能够指导个体化合理治疗。
目的:探討齊拉西酮的血藥濃度測定方法及其臨床應用。方法選取2011年10月~2013年7月期間內矇古精神衛生中心住院的30例矇古族分裂癥患者為研究對象。採用高效液相色譜法分彆于齊拉西酮治療第1、2、4週末測定患者體內齊拉西酮濃度,同時採用暘性與陰性癥狀量錶(PANSS)和治療時齣現的不良反應量錶(TESS)來評估臨床療效和不良反應。結果齊拉西酮血藥濃度在40~640 ng/mL範圍內與峰麵積呈現良好的線性關繫(r=0.99),最低定量濃度為18 ng/mL,日內日間誤差均小于10%。第4週週末所測齊拉西酮濃度與相應的PANSS減分率、日平均劑量呈顯著正相關(r>0.4,P<0.05)。結論所使用的高效液相色譜法具有簡單、穩定和準確的特點,而且患者體內齊拉西酮濃度具有良好的量效關繫,能夠指導箇體化閤理治療。
목적:탐토제랍서동적혈약농도측정방법급기림상응용。방법선취2011년10월~2013년7월기간내몽고정신위생중심주원적30례몽고족분렬증환자위연구대상。채용고효액상색보법분별우제랍서동치료제1、2、4주말측정환자체내제랍서동농도,동시채용양성여음성증상량표(PANSS)화치료시출현적불량반응량표(TESS)래평고림상료효화불량반응。결과제랍서동혈약농도재40~640 ng/mL범위내여봉면적정현량호적선성관계(r=0.99),최저정량농도위18 ng/mL,일내일간오차균소우10%。제4주주말소측제랍서동농도여상응적PANSS감분솔、일평균제량정현저정상관(r>0.4,P<0.05)。결론소사용적고효액상색보법구유간단、은정화준학적특점,이차환자체내제랍서동농도구유량호적량효관계,능구지도개체화합리치료。
Objective To investigate determination method of Ziprasidone plasma concentration and its clinical appli-cation. Methods 30 cases of Mongolian patients with schizophrenia hospitalized in Mental Health Center of Inner Mongolia Autonomous Region from October 2011 to July 2013 were selected, Ziprasidone plasma concentration in pa-tients was determined by HPLC at first, second, fourth weekend after Ziprasidone treatment respectively. Meanwhile, clinical efficacy and side effects were evaluated by positive and negative syndrome scale (PANSS) and treatment emer-gent symptom scale (TESS). Results A good linearity was obtained from 40 to 640 ng/mL plasma concentration with peak area (r=0.99). The quantitation limit was 18 ng/mL, with errors less than 10% for both intra-day and inter-day determinations. The Ziprasidone plasma concentration determined at fourth week had significant positive correlation with PANSS reductive ratio and daily dose (r>0.4, P<0.05). Conclusion The used HPLC method has the character-istics of simple, stable and accurate, and Ziprasidone plasma concentration in patients has good concentration-response relationship, which can guide individualized treatment.